share_log

DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of "Buy" From Analysts

DICE Therapeutics, Inc. (NASDAQ:DICE) Receives Consensus Rating of "Buy" From Analysts

Dice治疗公司(纳斯达克市场代码：DICE)获得分析师一致给予的“买入”评级
Defense World ·  2022/09/19 03:32

DICE Therapeutics, Inc. (NASDAQ:DICE – Get Rating) has received an average rating of "Buy" from the six analysts that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $43.33.

据MarketBeat.com报道，Dice治疗公司(纳斯达克代码：DICE-GET评级)从追踪该公司的六位分析师那里获得了“买入”的平均评级。六位投资分析师对该股的评级为买入。在去年更新了该股覆盖范围的经纪商中，平均12个月的价格目标是43.33美元。

DICE has been the subject of a number of analyst reports. HC Wainwright initiated coverage on DICE Therapeutics in a research note on Monday, July 18th. They set a "buy" rating and a $40.00 target price for the company. Stifel Nicolaus initiated coverage on DICE Therapeutics in a research note on Tuesday, September 6th. They set a "buy" rating and a $37.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on DICE Therapeutics in a research note on Wednesday, September 14th. They set an "overweight" rating and a $36.00 target price for the company.

Dice已经成为了许多分析师报告的主题。HC Wainwright在7月18日星期一的一份研究报告中开始了对DICE治疗的报道。他们为该公司设定了“买入”评级和40.00美元的目标价。Stifel Nicolaus在9月6日星期二的一份研究报告中开始了对DICE治疗的报道。他们为该公司设定了“买入”评级和37.00美元的目标价。最后，坎托·菲茨杰拉德在9月14日星期三的一份研究报告中开始了对DICE治疗的报道。他们为该公司设定了“增持”评级和36.00美元的目标价。

Get
到达
DICE Therapeutics
骰子治疗学
alerts:
警报：

DICE Therapeutics Trading Down 0.2 %

Dice Treeutics股价下跌0.2%

DICE Therapeutics stock opened at $19.98 on Wednesday. DICE Therapeutics has a twelve month low of $12.64 and a twelve month high of $40.50. The stock has a 50 day moving average of $18.22 and a two-hundred day moving average of $17.68. The stock has a market capitalization of $763.46 million and a price-to-earnings ratio of -5.23.

周三，Dice治疗公司的股票开盘报19.98美元。Dice Treateutics的12个月低点为12.64美元，12个月高位为40.50美元。该股的50日移动均线切入位为18.22美元，200日移动均线切入位为17.68美元。该股市值为7.6346亿美元，市盈率为-5.23。

Hedge Funds Weigh In On DICE Therapeutics

对冲基金入股Dice Treeutics

Hedge funds have recently bought and sold shares of the company. Prospera Financial Services Inc purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Amalgamated Bank purchased a new position in DICE Therapeutics in the 1st quarter valued at approximately $39,000. Legal & General Group Plc increased its stake in DICE Therapeutics by 265.1% in the 2nd quarter. Legal & General Group Plc now owns 4,764 shares of the company's stock valued at $74,000 after purchasing an additional 3,459 shares in the last quarter. Virtus ETF Advisers LLC increased its position in DICE Therapeutics by 18.5% during the second quarter. Virtus ETF Advisers LLC now owns 7,482 shares of the company's stock worth $116,000 after buying an additional 1,166 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in DICE Therapeutics during the second quarter worth $131,000. 95.42% of the stock is owned by hedge funds and other institutional investors.
对冲基金最近买卖了该公司的股票。普罗斯佩拉金融服务公司在第一季度购买了DICE治疗公司的一个新头寸，价值约3.9万美元。合并银行在第一季度购买了DICE治疗公司的一个新头寸，价值约3.9万美元。Legal&General Group Plc在第二季度将其在DICE治疗公司的持股增加了265.1%。Legal&General Group Plc现在持有该公司4,764股股票，价值74,000美元，上个季度又购买了3,459股。Virtus ETF Advisers LLC在第二季度将其在DICE治疗公司的地位增加了18.5%。Virtus ETF Advisers LLC现在持有该公司7,482股股票，价值11.6万美元，上个季度又购买了1,166股。最后，SG America Securities LLC在第二季度收购了DICE治疗公司的一个新头寸，价值13.1万美元。95.42%的股票由对冲基金和其他机构投资者持有。

About DICE Therapeutics

关于骰子治疗公司

(Get Rating)

(获取评级)

DICE Therapeutics, Inc, a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.

Dice Treateutics，Inc.是一家生物制药公司，建立了各种口服治疗候选药物，用于治疗免疫学和其他治疗领域的慢性病。其平台DELSCAPE旨在发现选择性口服小分子，以与系统生物学一样有效地调节蛋白质-蛋白质相互作用(PPI)。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on DICE Therapeutics (DICE)
  • Kroger's is Your One-Stop Consumer Staples Stock
  • Adobe Perfects the Art of the Faceplant for Investors
  • Tax Credits are the Incentives in the Inflation Reduction Act
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • 3 Banks Worth Considering For Q4
  • 免费获取StockNews.com关于DICE治疗(DICE)的研究报告
  • 克罗格百货是你的一站式消费者史泰博股票
  • Adobe为投资者完善Facebook工厂的艺术
  • 税收抵免是《降低通货膨胀法案》中的激励措施
  • 股市：红海中的三座强国
  • 第四季度值得考虑的3家银行

Receive News & Ratings for DICE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DICE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

接受DICE治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Dice Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发